(Q107980426)

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Coronavirus virulence genes with main focus on SARS-CoV envelope gene

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Murine Coronavirus Mouse Hepatitis Virus Is Recognized by MDA5 and Induces Type I Interferon in Brain Macrophages/Microglia

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice.

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Group 2 coronaviruses prevent immediate early interferon induction by protection of viral RNA from host cell recognition

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Mouse hepatitis virus does not induce Beta interferon synthesis and does not inhibit its induction by double-stranded RNA.

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques.

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Lung pathology of fatal severe acute respiratory syndrome.

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

The Dual Nature of Type I and Type II Interferons

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

A pneumonia outbreak associated with a new coronavirus of probable bat origin

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

New and evolving concepts of melanocytic nevi and melanocytomas

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

COVID-19 Autopsies, Oklahoma, USA

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Shared and Distinct Functions of Type I and Type III Interferons

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Pathological evidence for residual SARS-CoV-2 in pulmonary tissues of a ready-for-discharge patient

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

A Mouse Model of SARS-CoV-2 Infection and Pathogenesis

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Treating COVID-19 with colchicine in community healthcare setting

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Attenuated interferon and pro-inflammatory response in SARS-CoV-2-infected human dendritic cells is associated with viral antagonism of STAT1 phosphorylation

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Longitudinal analyses reveal immunological misfiring in severe COVID-19

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Activation and evasion of type I interferon responses by SARS-CoV-2

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Natural killer cell immunotypes related to COVID-19 disease severity

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

SARS-CoV-2 N protein antagonizes type I interferon signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Animal models for COVID-19

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Auto-antibodies against type I IFNs in patients with life-threatening COVID-19

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Evasion of Type I Interferon by SARS-CoV-2

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Deciphering the COVID-19 cytokine storm: Systematic review and meta-analysis

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

SARS-CoV-2 membrane glycoprotein M antagonizes the MAVS-mediated innate antiviral response

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Human Lung Stem Cell-Based Alveolospheres Provide Insights into SARS-CoV-2-Mediated Interferon Responses and Pneumocyte Dysfunction

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Three-Dimensional Human Alveolar Stem Cell Culture Models Reveal Infection Response to SARS-CoV-2

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

SARS-CoV-2-induced immune activation and death of monocyte-derived human macrophages and dendritic cells

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Genetic mechanisms of critical illness in Covid-19

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Cell-Type-Specific Immune Dysregulation in Severely Ill COVID-19 Patients

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Interferon-α2b Treatment for COVID-19 Is Associated with Improvements in Lung Abnormalities

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

The ORF8 protein of SARS-CoV-2 induced endoplasmic reticulum stress and mediated immune evasion by antagonizing production of interferon beta

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Genomic monitoring of SARS-CoV-2 uncovers an Nsp1 deletion variant that modulates type I interferon response

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

SARS-CoV-2 infection induces protective immunity and limits transmission in Syrian hamsters

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004

A distinct innate immune signature marks progression from mild to severe COVID-19

7 August 2021

1 reference

https://api.crossref.org/works/10.1016/J.CHOM.2021.05.004